| Long terminal repeat CRISPR-CAR-coupled “universal” T cells mediate potent anti-leukemic effects C Georgiadis, R Preece, L Nickolay, A Etuk, A Petrova, D Ladon, A Danyi, ... Molecular Therapy 26 (5), 1215-1227, 2018 | 126 | 2018 |
| TCRαβ/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy J Rasaiyaah, C Georgiadis, R Preece, U Mock, W Qasim JCI insight 3 (13), 2018 | 88 | 2018 |
| Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia R Chiesa, C Georgiadis, F Syed, H Zhan, A Etuk, SA Gkazi, R Preece, ... New England Journal of Medicine 389 (10), 899-910, 2023 | 74 | 2023 |
| Base-edited CAR T cells for combinational therapy against T cell malignancies C Georgiadis, J Rasaiyaah, SA Gkazi, R Preece, A Etuk, A Christi, ... Leukemia 35 (12), 3466-3481, 2021 | 72 | 2021 |
| Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia G Ottaviano, C Georgiadis, SA Gkazi, F Syed, H Zhan, A Etuk, R Preece, ... Science translational medicine 14 (668), eabq3010, 2022 | 68 | 2022 |
| CRISPR-mediated base conversion allows discriminatory depletion of endogenous T cell receptors for enhanced synthetic immunity R Preece, A Pavesi, SA Gkazi, KA Stegmann, C Georgiadis, ZM Tan, ... Molecular Therapy-Methods & Clinical Development 19, 149-161, 2020 | 15 | 2020 |
| ‘Mini’U6 Pol III promoter exhibits nucleosome redundancy and supports multiplexed coupling of CRISPR/Cas9 effects R Preece, C Georgiadis, SA Gkazi, A Etuk, A Christi, W Qasim Gene therapy 27 (9), 451-458, 2020 | 12 | 2020 |
| Tvt CAR7: phase 1 clinical trial of base-edited universal” CAR7 T cells for paediatric Relapsed/Refractory T-ALL R Chiesa, C Georgiadis, G Ottaviano, F Syed, T Braybrook, A Etuk, ... Blood 140 (Supplement 1), 4579-4580, 2022 | 11 | 2022 |
| Universal'Fratricide-Resistant CAR T Cells Against T Cell Leukemia Generated By Coupled & Uncoupled Deamination Mediated Base Editing C Georgiadis, J Rasaiyaah, SA Gkazi, R Preece, A Etuk, A Christi, ... Blood 134, 3219, 2019 | 4 | 2019 |
| Emerging CRISPR/Cas9 applications for T-cell gene editing R Preece, C Georgiadis Emerging Topics in Life Sciences 3 (3), 261-275, 2019 | 3 | 2019 |
| Therapeutic cells W Qasim, C Georgiadis, R Preece, U Mock, L Nickolay US Patent App. 16/470,933, 2020 | 1 | 2020 |
| CD62L-selected umbilical cord blood universal CAR T cells C Georgiadis, L Bor, F Syed, H Zhan, SA Gkazi, A Etuk, ... bioRxiv, 2024.01. 18.576145, 2024 | | 2024 |
| Investigation of chimeric Fc gamma RIIIa receptor (cFcR) engineered'Universal'T cells in combination with anti-CD20 monoclonal antibody A Etuk, C Georgiadis, R Preece, W Qasim HUMAN GENE THERAPY 33 (23-24), A125-A125, 2022 | | 2022 |
| Base edited" universal''CAR T cells against childhood AML R Kadirkamanathan, C Georgiadis, A Etuk, T Braybrook, R Preece, ... HUMAN GENE THERAPY 33 (23-24), A124-A125, 2022 | | 2022 |
| Comparison of cytidine deaminase base editors for multiplexed editing of T cells H Aldahshan, R Preece, H Brezovjakova, C Georgiadis, W Qasim HUMAN GENE THERAPY 33 (23-24), A131-A131, 2022 | | 2022 |
| CRISPR-coupled CAR engineering of universal donor T cells for paediatric B-ALL C Georgiadis, G Ottaviano, SA Gkazi, F Syed, H Zhan, A Etuk, R Preece, ... HUMAN GENE THERAPY 33 (23-24), A14-A14, 2022 | | 2022 |
| Minimal promoter W Qasim, C Georgiadis, R Preece, SA Gkazi US Patent App. 17/593,184, 2022 | | 2022 |
| Enhancing Strategies for CRISPR/Cas9 Based T cell Engineering R Preece UCL (University College London), 2020 | | 2020 |
| Multiplexed Cytidine Deamination Enables Generation of Fratricide-Resistant'Universal T v T'Chimeric Antigen Receptor Cell Therapy C Georgiadis, J Rasaiyaah, SA Gkazi, R Preece, A Etuk, A Christi, ... MOLECULAR THERAPY 28 (4), 212-212, 2020 | | 2020 |
| Recombinant T Cell Receptor Immunity Against Hepatitis B Surface Antigen Following Disruptive Base Editing of Endogenous T Cell Receptor SA Gkazi, R Preece, A Pavesi, K Stegmann, C Georgiadis, D Tan, JY Aw, ... MOLECULAR THERAPY 28 (4), 340-340, 2020 | | 2020 |
